Xerox Declares Dividend on Common and Preferred Stock

NORWALK, Conn.--(BUSINESS WIRE)-- Xerox's (NYSE: XRX) board of directors today declared a quarterly cash dividend of 7.75 cents per share on Xerox common stock. The dividend is payable on January 31, 2017 to shareholders of record on December 15, 2016.

The board also declared a quarterly cash dividend of $20 per share on Xerox Series A Convertible Perpetual Preferred Stock. The dividend is payable on January 1, 2017 to shareholders of record on December 15, 2016.

About Xerox

Xerox is helping change the way the world works. By applying our expertise in imaging, business process, analytics, automation and user-centric insights, we engineer the flow of work to provide greater productivity, efficiency and personalization. Our employees create meaningful innovations and provide business process services, printing equipment, software and solutions that make a real difference for our clients and their customers in 180 countries. On January 29, 2016, Xerox announced its plans to separate into two independent, publicly traded companies – Xerox Corporation, which will be comprised of the company’s Document Technology and Document Outsourcing businesses, and Conduent Incorporated, a business process services company. Learn more at www.xerox.com.

Note: To receive RSS news feeds, visit https://www.news.xerox.com. For open commentary, industry perspectives and views visit http://twitter.com/xerox, http://www.linkedin.com/company/xerox, http://simplifywork.blogs.xerox.com, http://www.facebook.com/XeroxCorp, http://www.youtube.com/XeroxCorp.

Xerox® and Xerox and Design® are trademarks of Xerox in the United States and/or other countries. Conduent is a trademark of Xerox Business Services, LLC in the United States and/or other countries.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161019006379/en/

Media:
Xerox
Sean Collins, +1-310-497-9205
[email protected]
or
Carl Langsenkamp, +1-585-423-5782
[email protected]

Source: Xerox

You May Also Be Interested In

• Carbios reaches milestone of 100 batches at its Industrial demonstration plant and expands its licensing offering to the textile market
• Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
• Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed